The riminophenazine compound clofazimine has been shown to be a potent inhibitor of hepatocellular carcinoma (HCC) in vitro. Therapeutic benefit was claimed for patients with HCC treated with clofazimine in a recent clinical trial. The current trial was initiated to evaluate response and survival of patients with HCC receiving clofazimine plus doxorubicin. Twenty-eight patients were entered into the study, of whom 27 were evaluable for response and survival. No patients had a complete or partial response, and 9 had stable disease. The median survival time was 7 weeks. Toxicity was mild with yellow pigmentation of the skin resulting from the clofazimine, and leukopenia, nausea, vomiting and mucositis as expected from doxorubicin. Further studies using other riminophenazine compounds are warranted.

Keywords:
Hepatocellular carcinoma, Clofazimine, Doxorubicin
1.
Falkson G, Falkson CI, Garbers L: Hepatocellular carcinoma; in Benson AB 3rd (ed): Cancer Treatment and Research, Gastrointestinal Oncology. Boston, Kluwer Academic, 1998, pp 83–109.
2.
Chedid A, Ryan LM, Dayal Y, Wolf BC, Falkson G: Histology and prognostic factors of hepatocellular carcinoma. Arch Pathol Lab Med, in press.
3.
Falkson G, Cnaan A, Schutt AJ, Ryan LM, Falkson HC: Prognostic factors for survival in hepatocellular carcinoma. Cancer Res 1988;48:7314–7318.
4.
van Rensburg CEJ, van Staden AM, Anderson R: The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines in vitro by phospholipase A2-mediated oxidative and nonoxidative mechanisms. Cancer Res 1993;53:318–323.
5.
Chasen MR, Jaskiewica K, Falkson G, Robson G: Differential expression of extracellular matrix and integrins in hepatocellular carcinoma and other diseases. XVI International Cancer Congres, New Delhi, 1994, p 355.
6.
Ruff P, Chasen MR, Long JE, van Rensburg CE: A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma. Ann Oncol 1998;9:217–219.
7.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
8.
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.